Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Siegfried in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $104.61.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Siegfried. This rating has held steady since June 2024, when it changed from a Hold consensus rating.
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products. In addition, it provides APIs and controlled substances focusing on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition; exclusive synthesis services comprising process and chemical development, analytical development, pilot manufacturing and scale-up, and commercial manufacturing; and viral vector manufacturing solutions. Further, the company licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for products. Siegfried Holding AG was founded in 1873 and is headquartered in Zofingen, Switzerland.
Read More
